Venetoclax with Azacytidine Improved Overall Survival for Patients with AML

Genentech recently announced their phase III study resulted in improved overall survival and composite complete remission rates for patients with previously untreated acute myeloid leukemia.

Source: CancerNetwork - March 23, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news